Succinic semialdehyde dehydrogenase and GABA transaminase system (SSADH/GABA-T system)

The Succinic semialdehyde dehydrogenase (SSADH) / GABA transaminase (GABA-T) system, collectively known as the GABA shunt, is a critical metabolic pathway responsible for the degradation of the primary inhibitory neurotransmitter, gamma-aminobutyric acid (GABA) (Source: UniProt P16050, P80404). In this pathway, GABA-T first converts GABA into succinic semialdehyde, which is subsequently oxidized by SSADH into succinate for entry into the tricarboxylic acid (TCA) cycle (Source: StatPearls, GABA Transaminase). This system plays a vital role in maintaining the balance between excitatory and inhibitory signaling in the central nervous system. Pharmacological targeting of GABA-T, most notably by the irreversible inhibitor vigabatrin, is a proven strategy for treating refractory epilepsy and infantile spasms by elevating brain GABA levels (Source: FDA Label, Sabril). Conversely, genetic deficiencies in SSADH lead to the accumulation of GABA and its byproduct, 4-hydroxybutyric acid (GHB), resulting in a rare neurometabolic disorder characterized by intellectual disability and seizures (Source: NIH, SSADH Deficiency). Understanding this system is essential for developing therapies that modulate GABAergic tone or address specific metabolic errors in neurotransmitter catabolism (Source: PubMed, PMID: 12605239). Therapeutic challenges include the risk of permanent visual field defects associated with long-term GABA-T inhibition and the management of toxic metabolite accumulation in SSADH deficiency (Source: PubMed, PMID: 21633502).

Other names

GABA shunt4-aminobutyrate aminotransferase and succinate-semialdehyde dehydrogenase systemGABA catabolic pathwayABAT and ALDH5A1 system

The primary mechanism of action for drugs targeting this system involves the irreversible inhibition of GABA transaminase (GABA-T), which prevents the conversion of GABA into succinic semialdehyde. This leads to a significant increase in the concentration of GABA within the brain, thereby enhancing inhibitory neurotransmission and suppressing seizure activity (Source: StatPearls, Vigabatrin). In the context of SSADH deficiency, the mechanism of disease involves the failure to convert succinic semialdehyde to succinate, leading to the alternative reduction of succinic semialdehyde into 4-hydroxybutyric acid (GHB), which exerts toxic effects on the central nervous system (Source: PubMed, PMID: 12605239).